Who
Edward M. Kaye
Director
Company insider
Files Form 4 as: Director, Cytokinetics; CEO, Stoke Therapeutics; Director, Avidity Biosciences; President & CEO, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 241
- Buys
- 1
- Sells
- 36
- Bought
- $9,456
- Sold
- $19.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 20 Jun 2011
- Last trade
- 16 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 20 Oct 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $12K195 at $63.92 | filing |
| 18 Aug 2026filed 18 Aug 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Sold | $382K11,930 at $32.01 | filing |
| 18 Aug 2026filed 18 Aug 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K637 at $32.47 | filing |
| 18 Aug 2026filed 18 Aug 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Sold | $382K11,930 at $32.01 | filing |
| 18 Aug 2026filed 18 Aug 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K637 at $32.47 | filing |
| 14 Aug 2026filed 18 Aug 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Code M | —26,250 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —26,250 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —26,250 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Code M | —26,250 at $0.00 | filing |
| 15 Jul 2026filed 16 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $12K151 at $82.62 | filing |
| 15 Jul 2026filed 16 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $12K151 at $82.62 | filing |
| 3 Jun 2026filed 5 Jun 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,786 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,786 at $0.00 | filing |
| 1 Jun 2026filed 1 Jun 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $223K2,933 at $76.09 | filing |
| 1 Jun 2026filed 1 Jun 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $223K2,933 at $76.09 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 15 Apr 2026filed 15 Apr 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $12K191 at $65.37 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK)CYTK · themarketsdaily.com · 25 Oct 2026Critical Contrast: Stoke Therapeutics (NASDAQ:STOK) vs. MeiraGTx (NASDAQ:MGTX)STOK · dailypolitical.com · 21 Oct 2026Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)CYTK · dailypolitical.com · 18 Oct 2026Contrasting Gain Therapeutics (NASDAQ:GANX) and Cytokinetics (NASDAQ:CYTK)CYTK · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Edward M. Kaye; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.